Page 205 - HIV/AIDS Guidelines
P. 205

Table 15b. Drug Interactions between Non-Nucleoside Reverse Transcriptase Inhibitors* and Other
            Drugs  (Page 6 of 6)


                                                  Effect on NNRTI or
                Concomitant Drug    NNRTI a       Concomitant Drug         Dosing Recommendations and Clinical
                  Class/Name                                                            Comments
                                                   Concentrations
             Narcotics/Treatment for Opioid Dependence

                                    EFV     buprenorphine AUC ↓ 50%       No withdrawal symptoms reported. No dosage
                                                          b
                                            norbuprenorphine AUC ↓ 71%    adjustment recommended, but monitor for
                                                                          withdrawal symptoms.
             Buprenorphine
                                    ETR     buprenorphine AUC ↓ 25%       No dosage adjustment necessary.

                                    NVP     No significant effect         No dosage adjustment necessary.
                                    EFV     methadone AUC ↓ 52%           Opioid withdrawal common; increased methadone
                                                                          dose often necessary.

                                    ETR     No significant effect         No dosage adjustment necessary.
             Methadone              NVP     methadone AUC ↓ 37%–51%       Opioid withdrawal common; increased methadone
                                            NVP: no significant effect    dose often necessary.
                                                       c
                                    RPV     R-methadone AUC ↓ 16%         No dosage adjustment necessary, but monitor for
                                                                          withdrawal symptoms.
             Phosphodiesterase Type 5 (PDE5) Inhibitors

                                    ETR     sildenafil AUC ↓ 57%          May need to increase sildenafil dose based on
                                                                          clinical effect.
             Sildenafil
                                    RPV     sildenafil ↔                  No dosage adjustment necessary.
             Tadalafil              ETR     ↓ tadalafil possible          May need to increase tadalafil dose based on
                                                                          clinical effect.

             Vardenafil             ETR     ↓ vardenafil possible         May need to increase vardenafil dose based on
                                                                          clinical effect.

             Miscellaneous Interactions
             Atovaquone/proguanil   EFV     ↓ atovaquone AUC 75%          No dosage recommendation. Consider alternative
                                            ↓ progaunil AUC 43%           drug for malaria prophylaxis, if possible.
            a
             Approved dose for RPV is 25 mg once daily. Most PK interaction studies were performed using 75 to 150 mg per dose.
            b
             Norbuprenorphine is an active metabolite of buprenorphine.
            c
             R-methadone is the active form of methadone.
            Key to Abbreviations: ARV = antiretroviral, AUC = area under the curve, BID = twice daily, CCB = calcium channel blocker, C max  = maximum
            plasma concentration, C min  = minimum plasma concentration, DLV = delavirdine, DMPA = depomedroxyprogesterone acetate,
            EFV = efavirenz, ETR = etravirine, FDA = Food and Drug Administration, INR = international normalized ratio, MAC = Mycobacterium avium
            complex, NNRTI = non-nucleoside reverse transcriptase inhibitor, NVP = nevirapine, PDE5 = phosphodiesterase type 5, PI = protease inhibitor,
            PPI = proton pump inhibitor, RPV = rilpivirine, RTV = ritonavir, TDF = tenofivir










            Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents        K-35

                            Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.
   200   201   202   203   204   205   206   207   208   209   210